Pune-based Emcure Pharmaceuticals has pulled out its proposed red herring prospectus or DRHP with securities market regulator SEBI. Emcure Pharmaceuticals on Wednesday said it has filed a draft red herring prospectus (DRHP) with the Sebi for launching an initial public offer. Pune-based Emcure Pharmaceuticals has filed draft red herring prospectus ( DRHP) with SEBI for initial public offering that includes fresh issue.
|Published (Last):||14 July 2017|
|PDF File Size:||12.63 Mb|
|ePub File Size:||18.98 Mb|
|Price:||Free* [*Free Regsitration Required]|
Emcure Pharmaceuticals files for IPO; Blackstone to part exit
The issue also involves a secondary sale 2. Get instant notifications from Economic Times Allow Not now. Emcurr Emcure Bain Capital private equity stake. Antibiotics made by Emcure Pharmaceuticals recalled in US. Fill in your details: Fortis again pushes back date to complete RHT Health deal; auditor resigns. Book running lead managers to the issue include Bank of America Merrill Lynch.
In AprilEmcure acquired Heritage Pharmaceuticals, a New Jersey-based generic pharmaceutical company, which provided it a commercial platform to market and sell its products.
Emcure Pharmaceuticals withdraws proposed IPO
Pune-based Emcure Pharmaceuticals has filed draft red herring prospectus DRHP with SEBI for initial public offering that includes fresh issue of upto Rs crore and an offer for sale of upto 25,13, equity share. The content may not be copied, broadcast, downloaded and stored in any mediumtransmitted, adapted or changed in any way whatsoever without the prior written permission of Mosaic Media Ventures Private Limited.
It is ranked as the 7th-largest pharmaceutical company in the therapeutic areas in which it operates. Will be displayed Will not be displayed Will be displayed. Thu, Dec 19 Emcure operates nine manufacturing facilities, eight of which are located in India and one in the United States. Of these revenues, By Jasleen Kaur Batra. This follows a deal struck late last year where Blackstone sold its stake to Bain Capital for an undisclosed amount. This will alert our moderators to take action. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express writtern permission of moneycontrol.
For the nine months ended December 31,Emcure’s revenue from operations was Rs 1, crore with net profit at Rs BSCPL is an infrastructure development company which operates in road, irrigation, real estate and hydro power projects.
Foul language Slanderous Inciting hatred against a certain community Others. Read more on Emcure Pharmaceuticals. Blackstone has exited now.
Find this comment offensive?
Emcure Pharmaceuticals files IPO papers with SEBI –
Fri, Dec 20 Interestingly, all the firms which decided not to go ahead with public floats are backed by private equity investors. My Saved Articles Sign in Sign up. Leave Your Comment s. Edited by Joby Puthuparampil Johnson. Infibeam calls off pact to acquire Snapdeal unit Unicommerce. Emcure is a fast growing Indian pharmaceutical company engaged in developing, manufacturing and marketing a broad range of pharmaceutical products globally.
The IPO comprises a fresh issue of equity shares aggregating up to Rs crore and an offer for sale of up to 2, equity shares by certain existing shareholders of the company, a statement issued here said. Emcure was the first private equity investment by a Blackstone-managed fund in India. Mandhana added that while an IPO is a convenient route for exits, secondary transactions provide more comfort to the new investor as potential corporate governance issues would have already been taken care of by the exiting PE firm.